Woman gets superbug with breast implant

June 16, 2012

Breast_Superbug

Mumbai, June 16: When a new mother from south Mumbai sought medical help for the significant distortion of her right breast, the term super-bug never crossed her mind. She may, however, be the most telling example of poor infection-control in Indian hospitals and the ensuing threat to patients undergoing surgeries.

The 30-year-old, who had undergone a breast implant surgery in 2009, was found to be suffering from an MRSA infection. MRSA (Methicillin-resistant Staphylococcus aureus) is one of the most potent superbugs or bacteria resistant to antibiotics. A few years back, the medical journal Lancet carried a series of controversial articles stating that newer superbugs such as NDM-1 (New Delhi Metallo-Beta-Lactamase 1) had emerged from India.

The young mother's right breast was not only more than double the size of the left, it was also lumpy and painful. An evaluation revealed that she first experienced firmness in her breast six months after the surgery, but she thought it was a result of her pregnancy. But the firmness worsened after she delivered her baby and started breast-feeding.

It was only when the doctors did an MRI scan did they realize that there was an infection in the lining (capsule) of the implant. "The MRI scan showed she was suffering from capsular contracture," said Dr Mohan Thomas, consultant cosmetic surgeon at Breach Candy Hospital. "She had undergone the cosmetic surgery in another hospital. By the time she came to us, the capsule (implant lining) of her right breast was about 12mm in size," he said, adding a normal lining does not go beyond 2mm in thickness.

The body reacts to any implant by forming a protective lining around it. This is referred to as the "capsule" or "tissue capsule" and is formed by one's own tissue. In some women, however, the capsule shrinks, squeezing the implant, referred to as capsular contracture. The tighter the capsule becomes, the firmer the breast feels.

It was only after her surgery that the reason for the capsular contracture was found. "While doing the surgery, a large amount of pus and fluid kept oozing out of her breast. We had to remove layers and layers of the capsule. After the surgery, we sent the fluid for examination and it turned out to be MRSA," said Dr Thomas. What surprised doctors was that clinical tests showed no signs of the infection, but only the fluid filled in the capsules showed the presence of the pathogens.

"If this pathogen had spread across the body, it could have killed the person. But in this woman's case, her capsule had taken the whole burden of this pathogen," said Dr Thomas. Worse, he said, she could have passed on the infection to her child since she was breast-feeding. After both her implants were removed, the doctors kept her in hospital until they were satisfied that she was free of infection.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 30,2020

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 12,2020

Kolkata, Jan 12: Prime Minister Narendra Modi on Sunday announced that Kolkata Port Trust will be renamed as Syama Prasad Mukherjee Port.

Addressing the gathering at the inauguration of 150th anniversary celebrations of Kolkata Port Trust, he said: "I announce the renaming of the Kolkata Port Trust to Dr Shyama Prasad Mukherjee Port. He is a living legend who was a leader for development and fought on the forefront for the idea of One Nation, One Constitution."

"This port represents industrial, spiritual and self-sufficiency aspirations of India. Today, when the port is celebrating its 150th anniversary, it is our responsibility to make it a powerful symbol of New India," Modi said.

The Prime Minister said that the Bharatiya Jana Sangh founder had set the stone for industrialization in India. "Chittaranjan Locomotive Factory, Hindustan Aircraft Factory, Damodar Valley Corporation and several others saw active participation from him," he said.

The Prime Minister also felicitated the two oldest pensioners of the Kolkata Port Trust, Nagina Bhagat and Naresh Chandra Chakraborty.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 1,2020

Chandigarh, Aug 1: The death toll in the Punjab spurious liquor tragedy rose to 86 on Saturday even as Chief Minister Amarinder Singh suspended seven excise officials and six policemen, officials said.

The government also announced a compensation of Rs 2 lakh for each of the families of the deceased, they said.

Tarn Taran alone accounted for 63 deaths, followed by 12 in Amritsar and 11 in Gurdaspur’s Batala. Till Friday night, the state had reported 39 deaths in the tragedy unfolding since Wednesday night.

According to an official statement, the CM ordered the suspension of seven excise officials, along with six policemen.

Among the suspended officials are two deputy superintendents of police and four station house officers.

Strict action will be taken against any public servant or others found complicit in the case, said the chief minister, describing the police and excise department failure to check the manufacturing and sale of spurious liquor as shameful.

Nobody will be allowed to get away with feeding poison to our people, he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.